BioSpace News Archive

SpyBiotech announced that the first subject has been dosed with SPYVLP01, a candidate vaccine targeting human cytomegalovirus using its Hepatitis B virus-like-particle platform technology.

Rentschler Biopharma SE, a leading contract development and manufacturing organization for biopharmaceuticals, including Advanced Therapy Medicinal Products, announced that Gunnar Voss von Dahlen has been appointed as Chief Financial Officer, effective December 1, 2023.

Providence Medical Technology, Inc., a medical device innovator focused on improving surgical outcomes for high-risk spine surgery patients, announced a new publication in the Journal of Clinical Neuroscience.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced a poster presentation with results from the Phase 1 portion of the Phase 1/2 dose escalation and expansion clinical trial of LYT-200 at the ESMO Immuno-Oncology Congress 2023.

Merck (NYSE: MRK) today announced full results from the non-registrational Phase 2 KeyVibe-002 trial evaluating vibostolimab/pembrolizumab, an investigational coformulation of vibostolimab, an anti-TIGIT antibody, and pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy, with or without docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progressive disease after treatment with immunotherapy and platinum-doublet chemotherapy.

Bristol Myers Squibb (NYSE: BMY) today announced that on December 6, 2023, its Board of Directors authorized the repurchase of an additional $3 billion of the company’s common stock under the company’s multi-year share repurchase program.

BioGenCell, a pioneer in personalized cell therapy solutions, is excited to announce the launch of its fifth Phase II clinical trial site in the United States at the University of Maryland.

Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces a business update for the year ending 31 December 2023.

MC2 Therapeutics today announced it has completed enrollment in its European Phase 2 trial assessing the safety and efficacy of MC2-25 CKD, an innovative new drug candidate for the treatment of urea associated skin diseases, incl.

Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry